Considerations for the hemophiliac patient with inhibitors to factor VIII

Anesthesia and Analgesia

Volumn 92, Issue 3, 2001, Pages 785-786

  Chaney, James D ^a   Nielsen, Vance G ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; IMMUNOGLOBULIN G ANTIBODY; PROTHROMBIN; THROMBOPLASTIN;

ADULT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CASE REPORT; HEMOPHILIA A; HEMOSTASIS; HUMAN; MALE; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PLASMAPHERESIS; PRIORITY JOURNAL; PROTHROMBIN TIME; X CHROMOSOMAL INHERITANCE;

EID: 0035129946     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/00000539-200103000-00044     Document Type: Article

References (7)

1. Hemophilia: A new approach to an old disease
2. Surgery in hemophilia A patients with factor VIII inhibitor: 10-Year experience
3. Successful hemostasis during a major orthopedic operation by using recombinant activated factor VII in a patient with severe hemophilia A and a potent inhibitor
4. Treatment of bleeding episodes in patients with hemophilia and an inhibitor: Comparison of two treatment protocols with recombinant activated factor VII
5. Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody
6. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors
7. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors